Finasteride – 4-azasteroid compound, selectively and competitive inhibitor of 5α-reductase. This nicotinamide adenine dinucleotide phosphate (NADP)-dependent enzyme converts testosterone to dihydrotestosterone. The drug specifically inhibits the enzyme 5α-reductase type 2, which leads to a significant reduction in the level of dihydrotestosterone in the prostate gland (>90%) and circulatory system (60% to 80%).

Finasteride increases testosterone levels prostate cancer (approximately 85%) in patients with BPH, it does not affect the growth and morphology of the prostate gland. The drug has a pronounced affinity for the androgen receptor. Finasteride reduces the PSA level in blood plasma of 41 %- 71% in patients with symptoms of BPH. However, the ratio values of unbound and total PSA level the drug has no effect.
The size of the prostate decreases under the influence of finasteride due to atrophy and apoptosis. Due to the action of the drug histological changes were observed after 6 months of starting treatment. Glandular elements of prostate tissue most sensitive to finasteride. The drug lowers the tone of the detrusor in patients with urinary retention caused by BPH.

Showing all 2 results